Subtopic Deep Dive
Neurofilament Mutations in Neuropathies
Research Guide
What is Neurofilament Mutations in Neuropathies?
Neurofilament mutations in neuropathies refer to genetic variants in NEFL, PRPH, and INA genes that disrupt neurofilament assembly, leading to axonal degeneration in hereditary peripheral neuropathies like Charcot-Marie-Tooth disease.
Mutations in neurofilament light chain (NEFL) and related proteins cause intermediate filament instability and axonal caliber reduction. These defects impair conduction velocity and trigger aggregation pathology. Over 20 papers document NEFL mutations in ~6% of CMT cases (Yuan et al., 2017; 693 citations).
Why It Matters
Neurofilament light chain (NfL) in plasma serves as a biomarker for axonal loss in inherited neuropathies, correlating with disease severity in Charcot-Marie-Tooth (CMT) patients (Sandelius et al., 2018; 227 citations). This enables monitoring therapeutic efficacy in clinical trials without invasive CSF sampling. In HSP and CMT, neurofilament defects reveal targets for stabilizing axonal transport (Lo Giudice et al., 2014; 336 citations; Ferreirinha et al., 2004; 269 citations).
Key Research Challenges
Identifying Rare Mutations
Detecting low-frequency NEFL and PRPH variants requires targeted sequencing amid genetic heterogeneity in CMT cohorts. Functional validation in models shows variable penetrance (Evgrafov et al., 2004; 580 citations). Over 50 neuropathy genes complicate prioritization.
Linking Mutations to Axonal Loss
Mutations disrupt neurofilament polymerization but causal mechanisms for caliber reduction remain unclear. Mouse models reveal transport defects yet human translation lags (Ferreirinha et al., 2004; 269 citations). Aggregation assays show inconsistent pathology.
Validating NfL Biomarkers
Plasma NfL elevations distinguish CMT subtypes but lack specificity versus other neuropathies. Longitudinal studies needed for trial endpoints (Sandelius et al., 2018; 227 citations). Assay standardization across cohorts poses variability.
Essential Papers
Neurofilaments and Neurofilament Proteins in Health and Disease
Aidong Yuan, Mala V. Rao, Veeranna et al. · 2017 · Cold Spring Harbor Perspectives in Biology · 693 citations
SUMMARYNeurofilaments (NFs) are unique among tissue-specific classes of intermediate filaments (IFs) in being heteropolymers composed of four subunits (NF-L [neurofilament light]; NF-M [neurofilame...
Mutant small heat-shock protein 27 causes axonal Charcot-Marie-Tooth disease and distal hereditary motor neuropathy
Oleg V. Evgrafov, Irina Mersiyanova, Joy Irobi et al. · 2004 · Nature Genetics · 580 citations
Intermediate Filament Proteins and Their Associated Diseases
M. Bishr Omary, Pierre A. Coulombe, W.H. Irwin McLean · 2004 · New England Journal of Medicine · 474 citations
he cytoskeleton consists of three abundant families of fibrillary proteins: microfilaments, microtubules, and intermediate filaments. 1,2ntermediate filament proteins derive their name from their d...
Hereditary spastic paraplegia: Clinical-genetic characteristics and evolving molecular mechanisms
Temistocle Lo Giudice, Federica Lombardi, Filippo M. Santorelli et al. · 2014 · Experimental Neurology · 336 citations
Gangliosides in the Brain: Physiology, Pathophysiology and Therapeutic Applications
Simonetta Sipione, John Monyror, Danny Galleguillos et al. · 2020 · Frontiers in Neuroscience · 306 citations
Gangliosides are glycosphingolipids highly abundant in the nervous system, and carry most of the sialic acid residues in the brain. Gangliosides are enriched in cell membrane microdomains ("lipid r...
Axonal degeneration in paraplegin-deficient mice is associated with abnormal mitochondria and impairment of axonal transport
Fátima Ferreirinha, Angelo Quattrini, Marinella Pirozzi et al. · 2004 · Journal of Clinical Investigation · 269 citations
In several neurodegenerative diseases, axonal degeneration occurs before neuronal death and contributes significantly to patients' disability. Hereditary spastic paraplegia (HSP) is a genetically h...
Practice Parameter: Evaluation of distal symmetric polyneuropathy: Role of laboratory and genetic testing (an evidence-based review)
J. D. England, G. Gronseth, Gary M. Franklin et al. · 2008 · Neurology · 261 citations
1) Screening laboratory tests may be considered for all patients with polyneuropathy (Level C). Those tests that provide the highest yield of abnormality are blood glucose, serum B12 with metabolit...
Reading Guide
Foundational Papers
Start with Evgrafov et al. (2004; 580 citations) for HSPB1 axonal CMT discovery, Omary et al. (2004; 474 citations) for IF disease framework, then England et al. (2008; 261 citations) for genetic testing guidelines.
Recent Advances
Sandelius et al. (2018; 227 citations) on plasma NfL biomarker; Stassart et al. (2018; 234 citations) on axon-myelin units in degeneration.
Core Methods
Genetic screening via NGS panels (England et al., 2008); ELISA/SIMOA for NfL quantification (Sandelius et al., 2018); confocal microscopy for filament dynamics (Yuan et al., 2017).
How PapersFlow Helps You Research Neurofilament Mutations in Neuropathies
Discover & Search
Research Agent uses searchPapers and citationGraph to map NEFL mutation literature from Yuan et al. (2017; 693 citations), revealing 50+ connected papers on CMT genetics. exaSearch uncovers rare PRPH variants; findSimilarPapers expands from Evgrafov et al. (2004; 580 citations) to HSP overlaps.
Analyze & Verify
Analysis Agent applies readPaperContent to extract mutation data from Omary et al. (2004; 474 citations), then verifyResponse with CoVe checks claims against England et al. (2008; 261 citations). runPythonAnalysis performs statistical correlation of NfL levels vs. CMT severity (Sandelius et al., 2018), with GRADE grading for biomarker evidence strength.
Synthesize & Write
Synthesis Agent detects gaps in axonal transport mechanisms post-Ferreirinha et al. (2004), flagging contradictions in filament assembly. Writing Agent uses latexEditText and latexSyncCitations to draft reviews citing 20 papers, latexCompile for publication-ready output, exportMermaid for neurofilament assembly diagrams.
Use Cases
"Analyze NfL plasma levels dataset from CMT patients for severity correlation"
Research Agent → searchPapers('neurofilament light CMT') → Analysis Agent → runPythonAnalysis(pandas correlation, matplotlib plots) → researcher gets p-value, R² stats, and GRADE-verified biomarker insights.
"Draft LaTeX review on NEFL mutations in hereditary neuropathies"
Synthesis Agent → gap detection → Writing Agent → latexEditText(structure sections) → latexSyncCitations(25 papers) → latexCompile(PDF) → researcher gets compiled manuscript with figures.
"Find GitHub code for neurofilament simulation models"
Research Agent → paperExtractUrls(Yuan 2017) → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets axonal transport simulation code with README analysis.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(NEFL mutations) → citationGraph → readPaperContent(50 papers) → GRADE summary on biomarker validity. DeepScan applies 7-step verification to Evgrafov et al. (2004) claims via CoVe checkpoints. Theorizer generates hypotheses linking INA mutations to HSP from Lo Giudice et al. (2014).
Frequently Asked Questions
What defines neurofilament mutations in neuropathies?
Mutations in NEFL, PRPH, INA genes disrupt heteropolymer assembly of NF-L, NF-M, NF-H subunits, causing axonal swelling and degeneration in CMT and dHMN (Yuan et al., 2017; Evgrafov et al., 2004).
What methods study these mutations?
Targeted sequencing identifies variants; patient-derived fibroblasts assess filament aggregation; mouse knock-ins model transport defects (Ferreirinha et al., 2004; England et al., 2008).
What are key papers?
Yuan et al. (2017; 693 citations) reviews NF biology; Evgrafov et al. (2004; 580 citations) links HSPB1 to axonal CMT; Omary et al. (2004; 474 citations) catalogs IF diseases; Sandelius et al. (2018; 227 citations) validates plasma NfL.
What open problems exist?
Therapeutic rescue of mutant neurofilaments unproven; NfL biomarker specificity low across neuropathies; genotype-phenotype correlations inconsistent in large cohorts (Sandelius et al., 2018; Lo Giudice et al., 2014).
Research Hereditary Neurological Disorders with AI
PapersFlow provides specialized AI tools for Neuroscience researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Systematic Review
AI-powered evidence synthesis with documented search strategies
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Neurofilament Mutations in Neuropathies with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Neuroscience researchers
Part of the Hereditary Neurological Disorders Research Guide